John Q. Trojanowski

TL;DR: The major accomplishments of ADNI have been the development of standardized methods for clinical tests, magnetic resonance imaging, positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting, and the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes.

TL;DR: Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of Lewy bodies, however, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonia symptom complex including cognitive impairment.

TL;DR: It is observed that TDP-43 proteinopathy was very common, frequently mixed with pathological Alzheimer's disease, and associated with a higher likelihood of the clinical expression of clinical Alzheimer's-type dementia but only when extended beyond the amygdala.

TL;DR: It is suggested that it is important to recognize that the neurodegenerative process caused by the Ala53Thr mutation in α-synuclein is not identical to that seen in typical idiopathic Parkinson's disease brains.

TL;DR: This work replicated the association with AD in an additional autopsy confirmed series and shows that this H1c haplotype increases both the expression of total MAPT transcript as well as specifically increasing the proportion of 4 microtubule binding repeat containing transcripts.